HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
09. November 2023 16:05 ET
|
HilleVax, Inc.
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
HilleVax to Present at Upcoming Investor Conferences
01. November 2023 16:48 ET
|
HilleVax, Inc.
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
26. September 2023 16:01 ET
|
HilleVax, Inc.
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
25. September 2023 07:00 ET
|
HilleVax, Inc.
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Pricing of Public Offering of Common Stock
19. September 2023 20:05 ET
|
HilleVax, Inc.
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax Announces Proposed Public Offering of Common Stock
19. September 2023 16:09 ET
|
HilleVax, Inc.
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
14. August 2023 07:00 ET
|
HilleVax, Inc.
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
12. Mai 2023 16:05 ET
|
HilleVax, Inc.
BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
09. Mai 2023 07:00 ET
|
HilleVax, Inc.
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
25. April 2023 06:45 ET
|
HilleVax, Inc.
Topline safety and clinical efficacy data from NEST-IN1 expected in the first quarter of 2024 HIL-214 is the most advanced vaccine candidate for norovirus infection There are currently no approved...